Medivation (MDVN) was initiated with a buy rating at Needham. Xtandi is rapidly gaining market share for the treatment of prostate cancer, Needham said.
Merck (MRK) was upgraded to buy at Bank of America/Merrill Lynch. Low expectations, a cheap valuation and dividend yield make this stock attractive, BofA/Merrill said. Estimates through 2015 were increased, price target is $47.
Micron (MU) was downgraded at Lazard Capital Markets to neutral. With DRAM strength set to taper off, consensus estimates are too bullish and the stock is expensive, Lazard Capital Markets said.
Radian Group (RDN) was upgraded at Keefe, Bruyette & Woods to outperform following Radian's capital raise. Estimates for 2014 and 2015 were introduced showing the company returning to sustained operating profitability, KBW said. New price target is $12.Charles Schwab (SCHW) was upgraded at Bernstein to outperform. The company will benefit from rising interest rates and a late cycle rebound in retail activity, Bernstein said. 2013 estimates were increased and the new price target is $23.
STOCK COMMENTS/EPS CHANGESBank of New York Mellon (BK) numbers were increased at Jefferies. Shares are now seen reaching $29. Estimates also increased, given higher equity returns, Jefferies said. Hold rating. Myriad Genetics (MYGN) numbers were cut at Credit Suisse. Shares are now seen reaching $28. Estimates were also reduced, given lower Medicare reimbursement rates, Credit Suisse said. Neutral rating. Northern Trust (NTRS) numbers were increased at Jefferies through 2014. Company is leveraged to higher equity prices and currency trading, Jefferies said. Hold rating. The Fresh Market estimates (TFM) estimates, target were reduced at UBS. Estimates for the fourth quarter and through 2014 were cut, based on commentary from other high-end food retailers and upcoming tough comparisons, UBS said. Maintain Buy rating, new $60 price target. >To submit a news tip, email: email@example.com.
Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV